PXD076080-1

PXD076080 is an original dataset announced via ProteomeXchange.

Title	Clinical and Proteomic Predictors of Primary Response to Infliximab in Crohn’s Disease with Small Bowel Involvement: A Pilot Study in China
Description	Background and Aim: Crohn’s disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract. Although various biomarkers have been used to predict infliximab (IFX) response in CD, its efficacy in patients with small bowel involvement remains underexplored. This study combined clinical data with serum proteomics to develop prediction models for IFX efficacy at week 14 in small bowel-involved CD. Methods: In this pilot study, 41 patients with small bowel-involved CD treated with IFX between January 2020 and December 2023 at two Chinese hospitals were included. Clinical response and remission at week 14 were assessed using the Crohn’s Disease Activity Index (CDAI). Pre-treatment serum proteomics identified differentially expressed proteins (fold change >1.2, p < 0.05). Predictive models were developed via logistic regression and validated with ROC curve analysis using SPSS 24.0 and R 4.4.0 (p < 0.05). Results: Clinical analysis identified extraintestinal manifestations (EIM), hemoglobin <87.5 g/L, and a history of CD-related surgery as key predictors of primary non-response (AUC = 0.846, 95% CI: 0.715–0.978). Proteomic analysis revealed 13 differentially expressed proteins (individual AUCs: 0.588-0.868). A serum model combining MSN, SAA4, VNN1, and IGFBP5 achieved an AUC of 0.931 (95% CI: 0.845-1.000). Integrating MSN with clinical predictors yielded combined models with AUCs between 0.882 and 0.914; notably, the MSN + CD-related surgery model performed best (AUC = 0.914, 95% CI: 0.829–0.998). Conclusions: The developed clinical, serum, and combined prediction models effectively forecast IFX efficacy in small bowel-involved CD, providing valuable tools for personalized treatment strategies.
HostingRepository	PRIDE
AnnounceDate	2026-03-26
AnnouncementXML	Submission_2026-03-25_18:16:42.365.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Yaqing Bai
SpeciesList	scientific name: Homo sapiens (Human); NCBI TaxID: NEWT:9606;
ModificationList	No PTMs are included in the dataset
Instrument	Q Exactive HF

Revision	Datetime	Status	ChangeLog Entry
0	2026-03-24 08:49:04	ID requested
⏵ 1	2026-03-25 18:16:42	announced

Dataset with its publication pending

submitter keyword: Prediction model, Small bowel involvement, Primary non-response, Proteomics, Infliximab,Crohn’s disease

Xiaoyin Bai
contact affiliation	No.1 Shuaifuyuan Wangfujing Dongcheng District, Beijing, China 100730
contact email	baixiaoyin@pumch.cn
lab head
Yaqing Bai
contact affiliation	Beijing Friendship Hospital, Capital Medical University
contact email	ashia_bai@126.com
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/03/PXD076080

PRIDE project URI

• PRIDE
  1. PXD076080
     1. Label: PRIDE project
     2. Name: Clinical and Proteomic Predictors of Primary Response to Infliximab in Crohn’s Disease with Small Bowel Involvement: A Pilot Study in China